A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients

• Status: Completed
• Trial end date: 2017-05-31

Summary

Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis who are admitted to the hospital for treatment.

• Phase: Phase 2

Details

• Lead Sponsor: Prolong Pharmaceuticals